Roche's debt from its 2009 buyout of Genentech is winding down–and less money to pay means more money to play with, outgoing chairman Franz Humer says.
written on 04.03.2014
Roche's debt from its 2009 buyout of Genentech is winding down–and less money to pay means more money to play with, outgoing chairman Franz Humer says.
See our Cookie Privacy Policy Here